Mutations in the KRAS oncogene drive the vast majority of pancreatic cancers. This research team is using knowledge of the immune system to isolate T cells that can target the cancer-promoting gene. This will allow the development of precision therapies involving highly selective white blood cells that can be given to pancreatic cancer patients to target and potentially destroy tumors.